Invest in Arcus Biosciences for a strong buying opportunity with promising data, robust pipeline, and significant market ...

Read here for more on the potential of RCUS's combination therapies for various cancers, with promising Phase 3 trials and ...

Truist Financial analyst Asthika Goonewardene maintained a Buy rating on Iovance Biotherapeutics (IOVA – Research Report) today. The company’s ...

In a report released today, Jason Zemansky from Bank of America Securities maintained a Hold rating on Arcus Biosciences (RCUS – Research ...

Precision BioSciences gains momentum as iECURE reports positive ECUR-506 data, and analysts forecast significant HBV ...

Long term Arcus Biosciences, Inc. (NYSE:RCUS) shareholders know that all too well, since the share price is down considerably over three years. Unfortunately, they have held through a 65% decline ...

HAYWARD, Calif., December 19, 2024--(BUSINESS WIRE)--Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and ...

Zimberelimab is under clinical development by Arcus Biosciences and currently in Phase II for Pancreatic Ductal Adenocarcinoma.

Domvanalimab is under clinical development by Arcus Biosciences and currently in Phase I for Glioblastoma Multiforme (GBM).

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies ...

Arcus Biosciences Stock Performance NYSE:RCUS opened at $15.46 on Friday. The company’s 50-day moving average is $16.41 and its two-hundred day moving average is $16.06. Arcus Biosciences, Inc ...

Arcus Biosciences has a twelve month low of $13.52 and a twelve month high of $20.31. The firm’s 50 day moving average price is $16.19 and its 200 day moving average price is $16.06.